Vistagen Therapeutics, Inc.VTGNEarnings & Financial Report
Nasdaq
VTGN Q3 2026 Key Financial Metrics
Revenue
$303.0K
Gross Profit
N/A
Operating Profit
$-19.5M
Net Profit
$-18.9M
Gross Margin
N/A
Operating Margin
-6450.8%
Net Margin
-6237.3%
YoY Growth
29.5%
EPS
$-0.45
Financial Flow
Vistagen Therapeutics, Inc. Q3 2026 Financial Summary
Vistagen Therapeutics, Inc. reported revenue of $303.0K for Q3 2026, with a net profit of $-18.9M (-6237.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $303.0K |
|---|---|
| Net Profit | $-18.9M |
| Gross Margin | N/A |
| Operating Margin | -6450.8% |
| Report Period | Q3 2026 |
Vistagen Therapeutics, Inc. Annual Revenue by Year
Vistagen Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $486.0K).
| Year | Annual Revenue |
|---|---|
| 2025 | $486.0K |
| 2024 | $1.1M |
| 2023 | $-227.0K |
| 2022 | $1.1M |
Income Statement
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $197900 | $84000 | $183000 | $234000 | $-15000 | $244000 | $258000 | $303000 |
| YoY Growth | 12.4% | -52.5% | -34.1% | -43.1% | -107.6% | 190.5% | 41.0% | 29.5% |
Balance Sheet
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $123.7M | $113.5M | $102.5M | $92.3M | $84.3M | $68.9M | $80.9M | $65.1M |
| Liabilities | $9.4M | $8.7M | $9.5M | $11.2M | $14.0M | $12.2M | $14.6M | $14.1M |
| Equity | $114.3M | $104.8M | $93.0M | $81.1M | $70.4M | $56.8M | $66.3M | $50.9M |
Cash Flow
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.2M | $-10.9M | $-10.9M | $-10.3M | $-10.1M | $-18.8M | $-13.8M | $-17.6M |